You just read:

Volasertib, Boehringer Ingelheim's Investigational Oncology Compound, is Granted Orphan Drug Designation for Acute Myeloid Leukemia in the U.S. and EU

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Apr 17, 2014, 08:00 ET